Working… Menu
Trial record 15 of 36 for:    pharmacosmos

An Extension Trial to Assess the Safety of Re-dosing of Iron Isomaltoside (Monofer®) (FerWonExt)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02962648
Recruitment Status : Completed
First Posted : November 11, 2016
Last Update Posted : May 31, 2019
Information provided by (Responsible Party):
Pharmacosmos A/S

Brief Summary:
Evaluation of safety and efficacy of IV iron isomaltoside re-dosing.

Condition or disease Intervention/treatment Phase
Iron-Deficiency Anemia Drug: Iron Isomaltoside Phase 3

Detailed Description:

Among the various formulations of parenteral iron available on the market, iron isomaltoside may allow flexibility in terms of high and rapid dosing. The use of parenteral iron, especially in high doses, may result in better compliance, fewer visits to the medical practitioner, and overall improvement in QoL.

Most trials with IV iron have been 4-12 weeks trials and long-term trials are warranted to fol-low-up on long-term safety.

This trial is a 6-months extension trial where the aim is to evaluate the safety and efficacy of IV iron isomaltoside re-dosing.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 104 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label, Multicentre, Extension Trial to Assess the Safety of Re-dosing of Intravenous Iron Isomaltoside (Monofer®)
Actual Study Start Date : December 2016
Actual Primary Completion Date : June 12, 2018
Actual Study Completion Date : June 12, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Iron

Arm Intervention/treatment
Experimental: Iron isomaltoside
Administered IV
Drug: Iron Isomaltoside
Other Name: Monofer

Primary Outcome Measures :
  1. The primary outcome measure is the number of adverse drug reaction (ADR). [ Time Frame: 6 months ]
  2. Change in Hb [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. Protocol defined cardiovascular adverse events (number of participants with such events) [ Time Frame: 6 months ]
  2. Change in Ferritin [ Time Frame: 6 months ]
  3. Change in Transferrin saturation (%) [ Time Frame: 6 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Completed one of the lead-in trials
  2. Randomised and dosed with iron isomaltoside in one of the lead-in trials.
  3. Hb of ≤ 11 g/dL
  4. Screening s-ferritin ≤ 100 ng/mL, or ≤ 300 ng/mL if TSAT≤ 30 %
  5. Willingness to participate and signing the informed consent form (ICF)

Exclusion Criteria:

  1. IV iron treatment between the lead-in trial and screening
  2. During 30-day period prior to screening or during the trial period; has or will be treated with a red blood cell transfusion, radiotherapy, and/or chemotherapy
  3. Received an investigational drug within 30 days of screening
  4. Decompensated liver cirrhosis or active hepatitis
  5. Pregnant or nursing women.
  6. Any other laboratory abnormality, medical condition, or psychiatric disorders which, in the opinion of the Investigator, will put the subject's disease management at risk or may result in the subject being unable to comply with the trial requirements

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02962648

Layout table for location information
United States, Florida
Miami, Florida, United States
Sponsors and Collaborators
Pharmacosmos A/S

Layout table for additonal information
Responsible Party: Pharmacosmos A/S Identifier: NCT02962648     History of Changes
Other Study ID Numbers: P-monofer-IDA/CKD-EXT-01
First Posted: November 11, 2016    Key Record Dates
Last Update Posted: May 31, 2019
Last Verified: December 2018
Keywords provided by Pharmacosmos A/S:
Additional relevant MeSH terms:
Layout table for MeSH terms
Anemia, Iron-Deficiency
Anemia, Hypochromic
Hematologic Diseases
Iron Metabolism Disorders
Metabolic Diseases
Trace Elements
Growth Substances
Physiological Effects of Drugs